S'abonner

Manifestations psychiatriques du nouveau variant de la maladie de Creutzfeldt-Jakob. À propos d'un cas - 17/02/08

Doi : ENC-02-2001-27-1-0013-7006-101019-ART58 

A. Dervaux [1],

S. Vicart [1],

F. Lopes [1],

M.-H. LeBorgne [1]

Voir les affiliations

Nous rapportons le cas d'une patiente de 36 ans, hospitalisée en psychiatrie pour syndrome dépressif majeur résistant au traitement, révélateur d'une maladie de Creutzfeldt-Jakob nouveau variant. Les premiers signes neurologiques, ataxie et myoclonies, sont apparus 7 mois après l'apparition de la symptomatologie dépressive. Les aspects cliniques et l'évolution des troubles présentés par la patiente sont concordants avec les cas de maladie de Creutzfeldt-Jakob nouveau variant décrits au Royaume-Uni depuis 1996.

Psychiatric features of the new variant Creutzfeldt-Jakob disease. A case report

The new variant of Creutzfeldt-Jakob disease (nvCJD) was first described in the UK in 1996 [ [16]]. The nvCJD differs from sporadic, genetic and iatrogenic CJD. Creutzfeldt-Jakob disease is closely associated with an abnormal isoform PrPSc of a cell-surface glycoprotein, prion protein [ [14]]. Molecular analysis suggests that nvCJD is caused by the same prion strain as bovine spongiform encephalopathy (BSE) [ [4], [10]]. To the end of September 2000, there have been 82 cases of nvCJD in the UK. We report the second French case of nvCJD to our knowledge [ [5], [13]]. Case report - This 36 year old woman was referred by a local general practitioner with a 6 month history of psychiatric symptoms of major depressive disorder. According to her family, the patient had suffered from personality change for several months before the onset of depression including apathy, emotional lability, infantile affect. There was no history of health problems. As she was admitted to the psychiatric department of our hospital in Paris suburbs, she presented a major depressive disorder. There were no specific psychiatric features allowing distinction from common depressive disorders, except a marked emotional lability. The patient's condition progressed rapidly within the following days. She presented memory impairment and disorientation. Drug treatments, clomipramine (125 mg/day) and venlafa-xine (200 mg/day), were used with no benefit. She presented subsequently transient delusions and auditory hallucinations, fleeting for some hours. The predominant delusional themes were somatic type and pregnancy. The delusions were concomitant with delusions of the onset of cognitive impairment. The patient tested negative for the P 14.3.3 protein in the CSF. Computed tomography scan of the brain did not show any relevant abnormality. The electroencephalogram showed non specific slow wave activity. The neurological symptoms developed 7 months after the onset of depressive symptoms including ataxia, myoclonus, excessive daytime drowsiness, headache. After the onset of neurological symptoms, the illness progressed rapidly over the next 2 months with cognitive impairment, particularly memory impairment, myoclonus, ataxia, incontinence of urine and progressive immobility leading to dependency. CSF tests were negative. She was referred to a neurology department where the diagnosis was confirmed by brain biopsy (detailed elsewhere). The patient died in a state of akinetic mutism. Discution - The clinical features of our patient were consistent with previous descriptions of nvCJD, mainly those of the National CJD Surveillance Unit studies [ [17]] : early psychiatric symptoms, prolonged duration of illness (median : 14 months), earlier age at death, compared with sporadic CJD. Psychiatric symptoms occur in the clinical course in about a third of cases of sporadic CJD [ [3]]. In contrast, of the 35 cases that have died of nvCJD identified in the study by Will et al. [ [17]], 34 suffered from early and prominent psychia-tric symptoms, mainly depression and anxiety. In most of the patients, the first symptoms were psychiatric. Drug treatment was used in most cases, some patients had a transient improvement [ [18]]. The patient without psychiatric symptoms reported by the NCJDSU (17) was emotionally labile. Infantile affect and emotional lability, found in our patient, are frequently reported in other studies [ [1], [18]]. Schizophreniform disorders have been described during the clinical course, with auditory and visual hallucinations and paranoid delusions [ [17], [18]]. The insomnia and excessive daytime drowsiness our patient presented have been described in similar cases [ [18]]. Investigations are important to rule out alternative dia-gnoses. EEG records do not show periodic triphasic complexes as in sporadic CJD. The P 14.3.3 protein in the CSF is positive in half the cases of nvCJD [ [17]]. First neurological symptoms developed 6 months after the onset of psychiatric symptoms including ataxia, myoclonus and persistent painful sensory symptoms [ [17], [18]]. In most of the cases, MRI brain scans show bilateral pulvinar high signal [ [17]], found subsequently in our patient and detailed elsewhere [ [13]]. The terminal stages are progressive cognitive impairment, helplessness and akinetic mutism. Conclusion - The first symptoms of this patient were purely psychiatric and difficult to distinguish from common psychiatric disorders. Clinical surveillance of human prion disease is crucial in France, as in UK. The link with BSE has dramatically highlighted the need for neurological and neuropsychological precise investigations.


Mots clés : Maladie de Creutzfeldt-Jakob. , Nouveau variant. , Trouble dépressif.

Keywords: Creutzfeldt-Jakob disease. , Major depressive disorder. , New variant.


Plan



© 2001 Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 27 - N° 1

P. 194 - février 2001 Retour au numéro
Article précédent Article précédent
  • Le sevrage ultra-rapide de patients dépendants aux opiacés : revue de la littérature, critiques et proposition d'un protocole expérimental
| Article suivant Article suivant
  • Un cas d'épisode psychotique aigu après prise unique d'ecstasy
  • G. Vaiva, D. Bailly, V. Boss, P. Thomas, P. Lestavel, M. Goudemand

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.